CE, MOC & Certificates

The Gastrointestinal Cancers Symposium will focus on multidisciplinary care that will highlight cutting-edge strategies, innovations, and research in gastrointestinal cancer care. Renowned faculty from around the world will offer their valuable perspectives on a wide array of topics covering cancers of the esophagus and stomach, pancreas, small bowel and hepatobiliary tract, and the colon, rectum and anus.

Accreditation and Designation Statement

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Society of Clinical Oncology designates this live activity for a maximum of 21.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA/NCCPA Credit Designation Statement – PAs

PAs may claim a maximum of 21.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

All non-physician attendees are welcome to submit a request for a Certificate of Participation, which may enable non-physicians to apply their meeting participation toward re-licensure. Please note, however, that all final decisions regarding certificate acceptance will be made by the licensing organization to which the certificate is submitted.

Target Audience

This symposium is designed for physicians and researchers interested in the prevention, screening, evaluation, and management of gastrointestinal cancers, including, but not limited to medical, surgical, and radiation oncologists; pathologists; radiologists; and other translational-oriented laboratory scientists.

This symposium may also benefit nurses, pharmacists, physician assistants, and other health care professionals involved in clinical cancer care and cancer research..

Educational Needs Statement

The treatment of gastrointestinal (GI) cancers requires a broad range of knowledge regarding new and established therapies, including newly approved immunotherapies, effective use of biomarkers and targeted therapies, to use of multimodality therapy including surgery, cytotoxic chemotherapy and radiation in the neoadjuvant and adjuvant settings. It is a complex landscape that requires continuous education. Unfortunately, many clinicians report feeling underprepared in this rapidly changing environment. Despite treating patients with immunotherapy agents, fewer than one-quarter of responding clinicians in a recent survey reported having deep familiarity with checkpoint inhibitors.  It has been well-documented in the colorectal cancer (CRC) setting and others, that genetic and molecular testing is underused, despite guidelines. Underuse of appropriate therapy in pancreatic, gastroesophageal, and other GI cancers has also been noted, regardless of the modality. Significant disparities in delivery of care and clinical outcomes also persist across GI disease states and stages. This year’s GI Symposium seeks to fill gaps not only in the science of precision medicine, but also in the personalization of medicine for the individual patient.

Learning Objectives

Upon participation in this activity, attendees will be better able to

  • Collaborate across different specialties and with all members of the oncology care team to deliver effective and patient-centered treatment for patients with gastrointestinal cancers;
  • Examine the effects of healthcare disparities on the outcomes of patients with gastrointestinal cancers;
  • Discuss the relationship between biology, biomarkers, and response in novel therapeutics, including targeted and immune-oncology agents, based on current evidence and how this translates to research and, ultimately, clinical care;
  • Consider the benefits and challenges of multimodality therapy in a number of GI malignancies, including appropriate patient selection and optimal treatment sequencing;
  • Compare and contrast the disease characteristics that indicate difference surgical options to determine the best approach and best sequencing with other therapies, where indicated, based on current evidence in the treatment of each patient with gastrointestinal cancer.
  • Review where novel and advanced diagnostic strategies can inform more precise treatment of patients with gastrointestinal cancers based on current evidence, including novel biomarker technologies and novel imaging techniques.

Disclaimer and Unlabeled Usage Statement

The information presented is that of the contributing faculty and presenters and does not necessarily represent the views of the Symposium Cosponsors and/or any named company or organization providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty or presenters.  Therefore, before presenting any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.